Evidence map›Paper›PMID 29955022›Full record

ArticleThe Kobe journal of medical sciences2018

A Case of Congenital Complete Atrioventricular Block Treated with Transdermal Tulobuterol.

Toshihiko Ikuta, Kazumichi Fujioka, Yumi Sato, Mariko Ashina, Sachiyo Fukushima, Shohei Ohyama, Saki Okubo, Keiji Yamana, Mayumi Morizane, Kenji Tanimura and 4 more

Open access · greenAbstract readCase Reports
PubMed Full text at PMC
In one paragraph

Article in The Kobe journal of medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 65% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Toshihiko IkutaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Kazumichi FujiokaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Yumi SatoDepartment of Pediatrics, Kakogawa Central City Hospital, Kakogawa, Japan.
Mariko AshinaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Sachiyo FukushimaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Shohei OhyamaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Saki OkuboDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Keiji YamanaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Mayumi MorizaneDepartment of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan.
Kenji TanimuraDepartment of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan.
Masashi DeguchiDepartment of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan.
Kazumoto IijimaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Ichiro MoriokaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Hideto YamadaDepartment of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan.
Kobe University · JPKagawa Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital complete atrioventricular block (CCAVB) is a condition in which the atria and ventricles beat independently of each other. CCAVB cases require permanent pacemaker implantation until adulthood. Nevertheless, consensus regarding postnatal medical therapy for bradycardia has not been reached. Here we report the case of a newborn with CCAVB, whose intractable bradycardia was successfully treated with transdermal tulobuterol. Tulobuterol is a selective β2-adrenoceptor agonist, widely used safely as bronchodilator in children. It also has positive inotropic and chronotropic effect via β1-adrenoceptors. We believe the tulobuterol patch can be used as an optional therapy for CCAVB where pacemaker implantation is not available.

Indexed as

Administration, CutaneousAdrenergic beta-AgonistsAdultAtrioventricular BlockFemaleHumansInfant, NewbornPregnancyTerbutalineAdrenergic beta-AgonistsTerbutalinetulobuterolcongenital complete atrioventricular blocknewbornSS-A/Ro antibodiestulobuterol

Identifiers

PMID29955022
PMCPMC6192816
OpenAlexW2982696282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.